Inappropriate prescribing in patients accessing specialist palliative day care services

International Journal of Clinical Pharmacy

Volumn 36, Issue 3, 2014, Pages 535-543

  Todd, A ^a   Nazar, H ^b   Pearson, S ^c   Andrew, I ^d   Baker, L ^d   Husband, A ^a  

^a DURHAM UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF SUNDERLAND   (United Kingdom)

^c UNIVERSITY OF SYDNEY   (Australia)

^d Centre for Specialist Palliative Care   (United Kingdom)

Author keywords

Drug interactions; Inappropriate prescribing; Life expectancy; Medication review; Palliative care

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; DAY CARE; FEMALE; HEALTH CARE ACCESS; HUMAN; INAPPROPRIATE PRESCRIBING; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MEDICATION ERROR; MIDDLE AGED; OUTCOME ASSESSMENT; PALLIATIVE THERAPY; PATIENT ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; TERTIARY HEALTH CARE; UNITED KINGDOM; VERY ELDERLY; DRUG INTERACTION; DRUG USE; STATISTICS AND NUMERICAL DATA; TERTIARY CARE CENTER;

ADULT; AGED; AGED, 80 AND OVER; DAY CARE; DRUG INTERACTIONS; DRUG UTILIZATION REVIEW; ENGLAND; FEMALE; HUMANS; INAPPROPRIATE PRESCRIBING; MALE; MIDDLE AGED; PALLIATIVE CARE; PREVALENCE; TERTIARY CARE CENTERS;

EID: 84901478632     PISSN: 22107703     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-014-9932-y     Document Type: Article

References (41)

1. Potter J, Hami F, Bryan T, Quigley C. Symptoms in 400 patients referred to palliative care services: prevalence and patterns. Palliat Med. 2003;17:310-4. (Pubitemid 36748433)
2. Sera L, McPherson ML, Holmes HM. Commonly prescribed medications in a population of hospice patients. Am J Hosp Palliat Care. 2013; Feb 12 (Epub ahead of print).
3. Koh NY, Koo WH. Polypharmacy in palliative care: can it be reduced? Singap Med J. 2002;43(6):279-83.
4. Rottlaender D, Scherner M, Schneider T, Erdmann E. Polypharmacy, compliance and non-prescription medication in patients with cardiovascular disease in Germany. Dtsch Med Wochenschr. 2007;132(4):139-44. (Pubitemid 46405884)
5. Riechelmann RP, Zimmermann C, Chin SN, Wang L, O'Carroll A, Zarinehbaf S, et al. Potential drug interactions in cancer patients receiving supportive care exclusively. J Pain Symptom Manag. 2008;35:535-43.
6. Girre V, Arkoub H, Puts MT, Vantelon C, Blanchard F, Droz JP, et al. Potential drug interactions in elderly cancer patients. Crit Rev Oncol Hematol. 2011;78:220-6.
7. Currow DC, Abernethy AP. Frameworks for approaching prescribing at the end of life. Arch Intern Med. 2006;166(21):2404. (Pubitemid 44833369)
8. Hall PS, Lord SR, El-Laboudi A, Seymour MT. Non-cancer medications for patients with incurable cancer: time to stop and think? Br J Gen Pract. 2010;60(573):243-4.
9. Maddison AR, Fisher J, Johnston G. Preventive medication use among persons with limited life expectancy. Prog Palliat Care. 2011;19(1):15-21.
10. Nicholson A, Andrew I, Etherington R, Gamlin R, Lovel T, Lloyd J. Futile and inappropriate prescribing: an assessment of the issue in a series of patients admitted to a specialist palliative care unit. Int J Pharm Pract. 2001;9(S1):72.
11. The end of life care. The national audit office, 2008. http://www.nao.org.uk/wp-content/uploads/2008/11/07081043.pdf. Accessed 10 Oct 2013.
12. Boulkedid R, Abdoul H, Loustau M, Sibony O, Alberti C. Using and reporting the Delphi method for selecting healthcare quality indicators: a systematic review. PLoS ONE. 2011;6(6):e20476.
13. Holmes HM, Hayley DC, Alexander GC, Sachs GA. Reconsidering medication appropriateness for patients late in life. Arch Intern Med. 2006;166(6):605-9.
14. Hsu CC, Sandford BA. The Delphi technique: making sense of consensus. Pract Assess Res Eval. 2007;12(10):1-8.
15. Rx systems. Proscript. http://rxsystems.co.uk/products. Accessed 10 Oct 2013.
16. Riechelmann RP, Tannock IF, Wang L, Saad ED, Taback NA, et al. Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst. 2007;99(8):592-600. (Pubitemid 47073540)
17. Baxter K, Preston CL. Stockley's drug interactions. 10th ed. UK: Pharmaceutical Press; 2013. ISBN 978 0 85711 061 9.
18. Electronic Medicines Compendium. http://www.medicines.org.uk/emc/. Last accessed 10 Oct 2013.
19. Todd A, Williamson S, Husband A, Baqir W, Mahony M. Patients with advanced lung cancer: is there scope to discontinue inappropriate medication? Int J Clin Pharm. 2013;35:181-4.
20. Riechelmann RP, Krzyzanowska MK, Zimmermann C. Futile medication use in terminally ill cancer patients. Support Care Cancer. 2009;17(6):745-8.
21. Fede A, Miranda M, Antonangelo D, Trevizan L, Schaffhausser H, Hamermesz B, et al. Use of unnecessary medications by patients with advanced cancer: cross-sectional survey. Support Care Cancer. 2011;19:1313-8.
22. van Leeuwen RW, Swart EL, Boven E, Boom FA, Schuitenmaker MG, Hugtenburg JG. Potential drug interactions in cancer therapy: a prevalence study using an advanced screening method. Ann Oncol. 2011;22(10):2334-41.
23. Nishio S, Watanabe H, Kosuge K, Uchida S, Hayashi H, Ohashi K. Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension. Hypertens Res. 2005;28(3):223-7. (Pubitemid 40812606)
24. Drug Safety Update. Simvastatin: evidence supporting recent advice on dose limitations with concomitant amlodipine or diltiazem. Med Healthc Regul Agency. http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON199561. Accessed 10 Oct 2013.
25. Steiness E. Diuretics, digitalis and arrhythmias. Acta Med Scand Suppl. 1981;647:75-8. (Pubitemid 11058785)
26. British National Formulary 64, September 2012. UK: Pharmaceutical Press. ISBN 978-0857110657.
27. Launay-Vacher V, Oudard S, Janus N, Gligorov J, Pourrat X, Rixe O, et al. Renal Insufficiency and Cancer Medications (IRMA) Study Group: prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer. 2007;110(6):1376-84. (Pubitemid 47435612)
28. Gokula M, Holmes HM. Tools to reduce polypharmacy. Clin Geriatr Med. 2012;28(2):323-41.
29. Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med. 2003;163:2716-24. (Pubitemid 37517412)
30. Hanlon JT, Schmader KE, Samsa GP. A method for assessing drug therapy appropriateness. J Clin Epidemiol. 1992;45:1045-51.
31. Gallagher P, Ryan C, Byrne S. STOPP (Screening Tool of Older Person's Prescriptions) and START (Screening Tool to Alert Doctors To Right Treatment). Consensus validation. Int J Clin Pharmacol Ther. 2008;46:72-83. (Pubitemid 351233792)
32. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383-9.
33. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM. PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk: pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623.
34. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7-22.
35. Callahan AS. Vascular pleiotropy of statins: clinical evidence and biochemical mechanisms. Curr Atheroscler Rep. 2003;5(1):33-7.
36. Weisman SM, Graham DY. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med. 2002;162(19):2197-202. (Pubitemid 35231588)
37. Nordin BEC. Calcium and osteoporosis. Nutrition. 1997;13(7/8):664-86. (Pubitemid 27347169)
38. Bayliss EA, Bronsert MR, Reifler LM, Ellis JL, Steiner JF, McQuillen DB, et al. Statin prescribing patterns in a cohort of cancer patients with poor prognosis. J Palliat Med. 2013;16(4):412-8.
39. Tanvetyanon T, Choudhury AM. Physician practice in the discontinuation of statins among patients with advanced lung cancer. J Palliat Care. 2006;22(4):281-5.
40. Stavrou EP, Buckley N, Olivier J, Pearson SA. Discontinuation of statin therapy in older people: does a cancer diagnosis make a difference? An observational cohort study using data linkage. BMJ Open. 2012;2:e000880.
41. Schuling J, Gebben H, Veehof LJ, Haaijer-Ruskamp FM. Deprescribing medication in very elderly patients with multimorbidity: the view of Dutch GPs. A qualitative study. BMC Fam Pract. 2012;13:56.